NASDAQ:BLUE - bluebird bio Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $37.81
Forecasted Upside: 113.27 %
Number of Analysts: 19
Breakdown:
0 Sell Ratings
17 Hold Ratings
2 Buy Ratings
0 Strong Buy Ratings

^$17.73 As of 09/16/2021 03:56 PM ET

▼ -0.07 (-0.39%)

1 month | 3 months | 12 months

Get New bluebird bio Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BLUE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLUE

^$37.81

▲ +113.27% Upside Potential

This price target is based on 19 analysts offering 12 month price targets for bluebird bio in the last 3 months. The average price target is $37.81, with a high forecast of $93.00 and a low forecast of $18.00. The average price target represents a 113.27% upside from the last price of $17.73.

Current Consensus is Hold

The current consensus among 19 investment analysts is to hold stock in bluebird bio. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
14 hold ratings
0 sell ratings

Ratings as of

3/24/2020

0 strong buy ratings
3 buy ratings
16 hold ratings
0 sell ratings

Ratings as of

6/22/2020

0 strong buy ratings
2 buy ratings
16 hold ratings
0 sell ratings

Ratings as of

9/20/2020

0 strong buy ratings
2 buy ratings
17 hold ratings
0 sell ratings

Ratings as of

12/19/2020

0 strong buy ratings
1 buy ratings
16 hold ratings
0 sell ratings

Ratings as of

3/19/2021

0 strong buy ratings
2 buy ratings
16 hold ratings
0 sell ratings

Ratings as of

6/17/2021

0 strong buy ratings
2 buy ratings
17 hold ratings
0 sell ratings

Ratings as of

8/16/2021

0 strong buy ratings
2 buy ratings
17 hold ratings
0 sell ratings

Ratings as of

9/15/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
8/10/2021	William Blair	Initiated Coverage	Market Perform		Medium
8/10/2021	BMO Capital Markets	Lower Price Target	Market Perform	$29.00 ➝ $21.00	High
8/10/2021	Bank of America	Lower Price Target	Neutral	$41.00 ➝ $22.00	High
8/10/2021	Canaccord Genuity	Downgrade	Buy ➝ Hold	$86.00 ➝ $20.00	High
8/10/2021	Mizuho	Lower Price Target	Buy	$70.00 ➝ $29.00	High
8/10/2021	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$63.00 ➝ $23.00	High
8/10/2021	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$60.00 ➝ $25.00	High
8/9/2021	Stifel Nicolaus	Lower Price Target	Hold	$31.00 ➝ $18.00	High
8/9/2021	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$64.00 ➝ $20.00	High
8/1/2021	SVB Leerink	Reiterated Rating	Buy		Low
7/16/2021	Morgan Stanley	Lower Price Target	Equal Weight	$36.00 ➝ $35.00	High
7/1/2021	Berenberg Bank	Downgrade	Buy ➝ Hold	$35.00	Low
6/15/2021	Oppenheimer	Reiterated Rating	Hold		Medium
6/10/2021	SVB Leerink	Initiated Coverage	Buy		Medium
4/21/2021	BMO Capital Markets	Lower Price Target	Market Perform	$35.00 ➝ $31.00	Medium
4/19/2021	Morgan Stanley	Lower Price Target	Equal Weight	$45.00 ➝ $36.00	Medium
3/29/2021	Piper Sandler	Boost Price Target		$30.00 ➝ $35.00	High
3/29/2021	Jefferies Financial Group	Reiterated Rating	Buy		High
3/29/2021	SVB Leerink	Boost Price Target	Outperform	$69.00 ➝ $72.00	N/A
3/29/2021	BMO Capital Markets	Boost Price Target	Market Perform	$31.00 ➝ $35.00	High
3/28/2021	Oppenheimer	Reiterated Rating	Hold		High
3/14/2021	SVB Leerink	Reiterated Rating	Buy		Medium
3/10/2021	Stifel Nicolaus	Boost Price Target		$26.00 ➝ $31.00	Medium
3/10/2021	Mizuho	Upgrade	Neutral ➝ Buy	$34.00 ➝ $69.00	High
3/2/2021	Morgan Stanley	Lower Price Target	Equal Weight	$50.00 ➝ $45.00	Medium
2/24/2021	Barclays	Lower Price Target	Equal Weight	$31.00 ➝ $27.00	Medium
2/17/2021	BMO Capital Markets	Boost Price Target	Market Perform	$36.00 ➝ $56.00	Low
2/17/2021	Stifel Nicolaus	Lower Price Target	Hold	$48.00 ➝ $35.00	Low
2/17/2021	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform		Low
2/17/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$76.00 ➝ $39.00	Low
2/16/2021	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low
2/16/2021	Bank of America	Downgrade	Buy ➝ Neutral		Low
2/16/2021	Wedbush	Downgrade	Outperform ➝ Neutral		Low
2/16/2021	Mizuho	Downgrade	Buy ➝ Neutral		Low
2/16/2021	Piper Sandler	Lower Price Target	Neutral	$55.00 ➝ $35.00	Low
2/16/2021	William Blair	Downgrade	Outperform ➝ Market Perform		Low
12/9/2020	Maxim Group	Downgrade	Buy ➝ Hold		High
12/7/2020	Mizuho	Reiterated Rating	Buy		High
11/11/2020	Berenberg Bank	Initiated Coverage	Buy	$64.00	Low
11/11/2020	Morgan Stanley	Lower Price Target	Equal Weight	$68.00 ➝ $50.00	Low
11/6/2020	Wedbush	Lower Price Target	Outperform	$81.00 ➝ $73.00	Medium
11/5/2020	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$77.00 ➝ $51.00	Medium
11/5/2020	Barclays	Downgrade	Overweight ➝ Equal Weight		High
11/5/2020	Canaccord Genuity	Lower Price Target	Buy	$118.00 ➝ $86.00	High
11/5/2020	JPMorgan Chase & Co.	Lower Price Target	Overweight	$140.00 ➝ $76.00	High
11/5/2020	Wells Fargo & Company	Lower Price Target	Overweight	$94.00 ➝ $81.00	High
11/5/2020	SVB Leerink	Lower Price Target	Outperform	$133.00 ➝ $99.00	High
11/5/2020	Bank of America	Lower Price Target	Buy	$100.00 ➝ $81.00	High
11/5/2020	Royal Bank of Canada	Lower Price Target	Outperform	$100.00 ➝ $93.00	High
11/5/2020	Oppenheimer	Lower Price Target	Outperform	$111.00 ➝ $90.00	High
11/5/2020	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$108.00 ➝ $56.00	High
11/4/2020	Piper Sandler	Lower Price Target	Neutral	$70.00 ➝ $55.00	High
11/2/2020	William Blair	Upgrade	Market Perform ➝ Outperform		Medium
10/19/2020	Mizuho	Initiated Coverage	Buy	$123.00	Medium
8/31/2020	Oppenheimer	Initiated Coverage	Buy	$111.00	High
8/30/2020	William Blair	Reiterated Rating	Hold		High
8/19/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
8/10/2020	Morgan Stanley	Lower Price Target	Equal Weight	$73.00 ➝ $68.00	Medium
8/6/2020	BMO Capital Markets	Lower Price Target	Outperform	$112.00 ➝ $108.00	High
8/6/2020	Wedbush	Lower Price Target	Outperform	$89.00 ➝ $81.00	Medium
7/29/2020	Oppenheimer	Initiated Coverage	Buy	$111.00	High
7/13/2020	Bank of America	Lower Price Target	Buy	$104.00 ➝ $100.00	High
6/12/2020	SVB Leerink	Boost Price Target	Outperform	$129.00 ➝ $133.00	Medium
6/1/2020	Oppenheimer	Initiated Coverage	Buy	$111.00	Low
5/28/2020	Morgan Stanley	Boost Price Target	Equal Weight	$69.00 ➝ $73.00	Medium
5/28/2020	SVB Leerink	Boost Price Target	Outperform	$125.00 ➝ $129.00	Low
5/17/2020	Oppenheimer	Initiated Coverage	Buy	$111.00	Medium
5/13/2020	Barclays	Reiterated Rating	Buy		High
5/12/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$100.00	High
5/12/2020	Canaccord Genuity	Reiterated Rating	Buy	$118.00	High
5/12/2020	BMO Capital Markets	Boost Price Target	Outperform	$107.00 ➝ $112.00	High
5/11/2020	Oppenheimer	Initiated Coverage	Buy	$122.00 ➝ $111.00	High
5/11/2020	Piper Sandler	Lower Price Target	Neutral	$75.00 ➝ $70.00	High
4/15/2020	Morgan Stanley	Lower Price Target	Equal Weight	$92.00 ➝ $69.00	Low
3/27/2020	BMO Capital Markets	Lower Price Target	Outperform	$132.00 ➝ $107.00	Low
3/27/2020	William Blair	Reiterated Rating	Hold		Medium
3/26/2020	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$94.00 ➝ $70.00	Low
3/26/2020	Piper Sandler	Lower Price Target		$85.00 ➝ $75.00	Low
3/26/2020	Wells Fargo & Company	Reiterated Rating	Buy		Medium
2/26/2020	Morgan Stanley	Lower Price Target	Equal Weight	$100.00 ➝ $92.00	Low
2/20/2020	Oppenheimer	Lower Price Target		$135.00 ➝ $128.00	Low
2/19/2020	Raymond James	Downgrade	Strong-Buy ➝ Market Perform		High
2/19/2020	Stifel Nicolaus	Lower Price Target	Hold	$96.00 ➝ $94.00	High
2/3/2020	Bank of America	Initiated Coverage	Buy	$120.00	High
2/3/2020	Evercore ISI	Upgrade	In-Line ➝ Outperform	$86.00 ➝ $100.00	High
1/19/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
12/12/2019	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$135.00	High
12/10/2019	William Blair	Reiterated Rating	Hold		High
12/9/2019	Wells Fargo & Company	Lower Price Target	Overweight	$242.00 ➝ $160.00	High
12/9/2019	Canaccord Genuity	Lower Price Target	Buy	$171.00 ➝ $118.00	High
12/6/2019	Cowen	Reiterated Rating	Buy		Low
11/27/2019	Evercore ISI	Downgrade	Outperform ➝ In-Line		Medium
11/26/2019	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$119.00	Low
11/21/2019	Cowen	Reiterated Rating	Buy		Medium
11/4/2019	Wedbush	Upgrade	Neutral ➝ Outperform	$131.00 ➝ $124.00	High
11/1/2019	Stifel Nicolaus	Set Price Target	Hold	$96.00	Low
11/1/2019	Morgan Stanley	Set Price Target	Hold	$104.00 ➝ $100.00	Low
11/1/2019	Maxim Group	Reiterated Rating	Buy	$130.00	Low
10/11/2019	Morgan Stanley	Lower Price Target	Equal Weight	$136.00 ➝ $104.00	Medium
10/9/2019	Stifel Nicolaus	Reiterated Rating	Hold		N/A
9/30/2019	Stifel Nicolaus	Initiated Coverage	Hold	$109.00	High
9/18/2019	William Blair	Reiterated Rating	Hold		Low
8/12/2019	William Blair	Downgrade	Outperform ➝ Market Perform		High
8/6/2019	Morgan Stanley	Lower Price Target	Equal Weight	$143.00 ➝ $136.00	Medium
7/19/2019	Gabelli	Reiterated Rating	Buy		N/A
6/18/2019	Maxim Group	Upgrade	Hold ➝ Buy	$160.00	High
6/17/2019	BMO Capital Markets	Lower Price Target	Outperform	$191.00 ➝ $163.00	Low
6/14/2019	Piper Jaffray Companies	Set Price Target	Hold	$120.00	Low
6/13/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$195.00	High
5/17/2019	JPMorgan Chase & Co.	Set Price Target	Buy	$195.00	Medium
5/16/2019	SunTrust Banks	Lower Price Target	Buy	$174.00	Medium
5/15/2019	Wedbush	Downgrade	Outperform ➝ Neutral	$166.00 ➝ $131.00	Medium
5/3/2019	BMO Capital Markets	Set Price Target	Buy	$191.00	High
5/3/2019	William Blair	Reiterated Rating	Buy		Medium
4/23/2019	William Blair	Reiterated Rating	Outperform		Low
3/22/2019	Cantor Fitzgerald	Set Price Target	Hold	$122.00	Low
3/5/2019	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Low
2/26/2019	Cowen	Initiated Coverage	Outperform	$149.91	High
2/25/2019	SunTrust Banks	Lower Price Target	Buy	$184.00	High
2/22/2019	BMO Capital Markets	Boost Price Target	Outperform	$194.00	Medium
2/22/2019	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$134.00 ➝ $122.00	Medium
1/23/2019	Canaccord Genuity	Reiterated Rating	Buy ➝ Buy	$250.00 ➝ $161.00	High
1/11/2019	Oppenheimer	Reiterated Rating	Hold		Low
1/10/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		High
12/19/2018	Raymond James	Initiated Coverage	Strong-Buy ➝ Strong-Buy	$165.00	High
12/9/2018	Cowen	Reiterated Rating	Buy		Low
12/6/2018	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$240.00 ➝ $120.00	Medium
12/4/2018	Oppenheimer	Reiterated Rating	Hold		Low
12/4/2018	William Blair	Reiterated Rating	Buy		Low
12/3/2018	Janney Montgomery Scott	Set Price Target	Outperform ➝ Buy	$170.00	High
12/3/2018	Maxim Group	Reiterated Rating	Hold		High
12/3/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$134.00	High
11/27/2018	Oppenheimer	Reiterated Rating	Hold		High
11/27/2018	SVB Leerink	Initiated Coverage	Outperform	$145.00 ➝ $145.00	Low
11/14/2018	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$155.00	High
11/5/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$186.00 ➝ $185.00	Low
11/5/2018	Wedbush	Lower Price Target	Outperform ➝ Outperform	$204.00 ➝ $166.00	Medium
11/5/2018	Janney Montgomery Scott	Upgrade	Neutral ➝ Buy	$170.00 ➝ $170.00	Medium
11/4/2018	Piper Jaffray Companies	Reiterated Rating	Buy		Medium
11/2/2018	Cowen	Reiterated Rating	Buy		Medium
11/2/2018	Oppenheimer	Reiterated Rating	Hold		Low
11/2/2018	Cantor Fitzgerald	Upgrade	Underweight ➝ Neutral	$122.00 ➝ $134.00	Medium
11/1/2018	Maxim Group	Reiterated Rating	Hold		Medium
11/1/2018	William Blair	Reiterated Rating	Buy		High
10/15/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$190.00 ➝ $186.00	Low
9/21/2018	The Goldman Sachs Group	Downgrade	Conviction-Buy ➝ Buy		Medium
9/17/2018	Guggenheim	Initiated Coverage	Neutral		Medium
9/5/2018	Cantor Fitzgerald	Set Price Target	Sell	$122.00	Low
9/5/2018	William Blair	Reiterated Rating	Buy		Medium
8/23/2018	Cantor Fitzgerald	Set Price Target	Sell	$122.00	Low
8/6/2018	Maxim Group	Reiterated Rating	Hold		Low
8/6/2018	Cowen	Reiterated Rating	Buy		Low
8/6/2018	Cantor Fitzgerald	Set Price Target	Sell	$122.00	Medium
8/3/2018	SunTrust Banks	Reiterated Rating	Buy	$223.00	High
8/3/2018	BMO Capital Markets	Reiterated Rating	Buy	$208.00	High
8/2/2018	Piper Jaffray Companies	Reiterated Rating	Buy		Medium
7/30/2018	Maxim Group	Lower Price Target	Hold	$163.00	Low
7/13/2018	Cantor Fitzgerald	Set Price Target	Sell	$122.00	Medium
7/12/2018	Gabelli	Initiated Coverage	Buy	$239.00	Low
6/19/2018	Evercore ISI	Upgrade	In-Line ➝ Outperform	$175.00 ➝ $230.00	Low
6/5/2018	Piper Jaffray Companies	Set Price Target	Buy	$240.00	Low
6/4/2018	Cantor Fitzgerald	Upgrade	Underweight ➝ Overweight		Low
6/4/2018	Cowen	Reiterated Rating	Buy		High
6/3/2018	Cantor Fitzgerald	Set Price Target	Sell	$122.00	High
5/30/2018	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Buy	$240.00	High
5/16/2018	Cantor Fitzgerald	Reiterated Rating	Underweight		Low
5/10/2018	Cantor Fitzgerald	Reiterated Rating	Sell	$122.00	Medium
5/7/2018	Sanford C. Bernstein	Reiterated Rating	Market Perform	$211.00	Low
5/3/2018	Maxim Group	Set Price Target	Hold	$200.00	High
5/3/2018	BMO Capital Markets	Lower Price Target	Outperform ➝ Buy	$222.00 ➝ $216.00	High
5/3/2018	BTIG Research	Reiterated Rating	Buy		High
4/19/2018	SunTrust Banks	Boost Price Target	Buy	$232.00	High
3/28/2018	Canaccord Genuity	Reiterated Rating	Buy		Low
3/21/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$152.00 ➝ $209.00	High
3/16/2018	William Blair	Reiterated Rating	Buy		Medium
3/16/2018	UBS Group	Initiated Coverage	Sell		High
3/14/2018	Janney Montgomery Scott	Initiated Coverage	Neutral ➝ Neutral	$220.00	Medium
3/13/2018	Canaccord Genuity	Reiterated Rating	Buy	$250.00	Low
3/8/2018	BTIG Research	Boost Price Target	Buy	$250.00	Medium
3/5/2018	William Blair	Initiated Coverage	Outperform ➝ Outperform	$206.10 ➝ $242.00	High
2/26/2018	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$151.00 ➝ $152.00	Medium
2/22/2018	Maxim Group	Reiterated Rating	Hold	$200.00	Medium
2/22/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$185.00 ➝ $218.00	Medium
2/22/2018	BMO Capital Markets	Set Price Target	Outperform ➝ Buy	$215.00 ➝ $222.00	High
2/22/2018	Sanford C. Bernstein	Reiterated Rating	Hold	$153.00 ➝ $211.00	High
2/22/2018	Cantor Fitzgerald	Lower Price Target	Underweight	$122.00 ➝ $113.00	High
2/21/2018	Cantor Fitzgerald	Reiterated Rating	Underweight ➝ Sell	$122.00 ➝ $113.00	High
2/1/2018	Canaccord Genuity	Reiterated Rating	Buy	$250.00	High
1/25/2018	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$162.00 ➝ $194.00	Low
1/9/2018	Oppenheimer	Reiterated Rating	Hold		Low
12/21/2017	CIBC	Initiated Coverage	Market Perform ➝ Market Perform		High
12/20/2017	Oppenheimer	Initiated Coverage	Market Perform		Low
12/13/2017	Maxim Group	Downgrade	Buy ➝ Hold	$200.00	Medium
12/13/2017	Barclays	Reiterated Rating	Overweight ➝ Overweight	$162.00 ➝ $209.00	High
12/12/2017	SunTrust Banks	Boost Price Target	Buy	$223.00	High
12/12/2017	Wells Fargo & Company	Reiterated Rating	Outperform	$190.00 ➝ $242.00	High
12/11/2017	BMO Capital Markets	Set Price Target	Buy	$215.00	High
12/11/2017	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$130.00 ➝ $211.00	High
12/11/2017	Cantor Fitzgerald	Set Price Target	Underweight ➝ Underweight	$58.00 ➝ $113.00	High
12/5/2017	Canaccord Genuity	Initiated Coverage	Buy ➝ Buy	$202.00	Low
11/30/2017	Maxim Group	Boost Price Target	Buy ➝ Buy	$170.00 ➝ $200.00	High
11/17/2017	Maxim Group	Set Price Target	Buy	$170.00	N/A
11/3/2017	SunTrust Banks	Boost Price Target	Buy ➝ Buy	$108.00 ➝ $163.00	N/A
11/3/2017	Jefferies Financial Group	Reiterated Rating	Hold	$130.00	N/A
11/3/2017	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight		N/A
11/2/2017	Barclays	Boost Price Target	Overweight	$151.00 ➝ $162.00	N/A
11/2/2017	Maxim Group	Reiterated Rating	Buy	$170.00	N/A
11/2/2017	Wedbush	Reiterated Rating	Outperform	$135.00 ➝ $174.00	N/A
11/2/2017	BTIG Research	Upgrade	Neutral ➝ Buy	$177.00	N/A
11/1/2017	SVB Leerink	Reiterated Rating	Outperform	$145.00 ➝ $162.00	N/A
11/1/2017	Cantor Fitzgerald	Reiterated Rating	Sell	$39.00 ➝ $58.00	N/A
10/30/2017	BMO Capital Markets	Boost Price Target	Buy	$134.00 ➝ $162.00	N/A
10/16/2017	Evercore ISI	Upgrade	In-Line ➝ Outperform	$102.00	N/A
10/11/2017	Jefferies Financial Group	Reiterated Rating	Buy ➝ Hold	$126.00	N/A
10/9/2017	Maxim Group	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $170.00	N/A
10/6/2017	SVB Leerink	Reiterated Rating	Outperform	$120.00 ➝ $145.00	N/A
10/6/2017	The Goldman Sachs Group	Reiterated Rating	Buy ➝ Buy	$186.00	N/A
10/2/2017	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$105.00	High
9/30/2017	SVB Leerink	Reiterated Rating	Outperform	$120.00	High
9/28/2017	Cantor Fitzgerald	Reiterated Rating	Sell	$39.00	High
9/6/2017	Barclays	Initiated Coverage	Overweight	$151.00	Low
9/5/2017	Wells Fargo & Company	Reiterated Rating	Outperform ➝ Outperform	$134.00 ➝ $158.00	Medium
9/1/2017	Wedbush	Reiterated Rating	Outperform	$121.00 ➝ $135.00	High
8/31/2017	Cowen	Reiterated Rating	Outperform		High
8/16/2017	Evercore ISI	Initiated Coverage	In ➝ In-Line	$102.00	High
8/11/2017	Jefferies Financial Group	Reiterated Rating	Buy	$88.00	Medium
8/9/2017	Morgan Stanley	Reiterated Rating	Hold		High
8/7/2017	Morgan Stanley	Boost Price Target	Equal ➝ Equal Weight	$103.00 ➝ $105.00	Medium
8/4/2017	BMO Capital Markets	Reiterated Rating	Buy	$108.00	Medium
7/27/2017	Sanford C. Bernstein	Initiated Coverage	Market Perform	$109.00	High
7/24/2017	Cantor Fitzgerald	Reiterated Rating	Sell	$39.00	High
7/10/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$105.00 ➝ $103.00	Low
7/6/2017	Jefferies Financial Group	Reiterated Rating	Buy		Low
6/30/2017	BTIG Research	Downgrade	Buy ➝ Neutral	$37.05 ➝ $108.25	Medium
6/28/2017	BTIG Research	Reiterated Rating	Buy ➝ Buy	$112.00	High
6/26/2017	Janney Montgomery Scott	Set Price Target	Buy	$125.00	N/A
6/24/2017	Cantor Fitzgerald	Set Price Target	Sell	$37.00 ➝ $39.00	Low
6/23/2017	Cowen	Reiterated Rating	Buy		Low
6/23/2017	Wedbush	Reiterated Rating	Outperform	$121.00 ➝ $100.00	Low
6/16/2017	Standpoint Research	Reiterated Rating	Buy ➝ Reduce	$110.00	Low
6/14/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$91.00 ➝ $105.00	Low
6/9/2017	Cowen	Reiterated Rating	Outperform		Low
6/7/2017	Janney Montgomery Scott	Boost Price Target	Neutral ➝ Buy	$81.00 ➝ $125.00	High
6/6/2017	Wedbush	Reiterated Rating	Outperform		High
6/6/2017	BMO Capital Markets	Reiterated Rating	Buy	$108.00	High
6/5/2017	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$61.00 ➝ $108.00	High
6/5/2017	Bank of America	Reiterated Rating	Hold	$95.00	High
6/5/2017	Cantor Fitzgerald	Set Price Target	Sell	$37.00	High
6/2/2017	Maxim Group	Upgrade	Hold ➝ Buy	$100.00	High
6/1/2017	BTIG Research	Reiterated Rating	Buy	$112.00	High
5/30/2017	Standpoint Research	Initiated Coverage	Buy ➝ Buy	$110.00	Low
5/15/2017	Maxim Group	Reiterated Rating	Hold		N/A
5/8/2017	Morgan Stanley	Boost Price Target	Equal Weight	$87.00 ➝ $91.00	Medium
5/5/2017	Maxim Group	Reiterated Rating	Hold		High
5/1/2017	BTIG Research	Reiterated Rating	Buy		Medium
3/24/2017	Jefferies Financial Group	Reiterated Rating	Buy	$88.00	High
3/1/2017	Morgan Stanley	Boost Price Target	Equal Weight	$58.00 ➝ $87.00	N/A
2/27/2017	Maxim Group	Downgrade	Buy ➝ Hold	$87.00	N/A
2/23/2017	Roth Capital	Set Price Target	Hold	$71.00	N/A
2/23/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$83.00	N/A
2/6/2017	Roth Capital	Reiterated Rating	Buy ➝ Neutral	$87.00 ➝ $71.00	N/A
2/3/2017	Maxim Group	Set Price Target	Buy	$87.00	N/A
1/10/2017	Jefferies Financial Group	Reiterated Rating	Buy	$88.00	N/A
12/15/2016	Roth Capital	Reiterated Rating	Buy	$87.00	N/A
12/13/2016	Maxim Group	Reiterated Rating	Buy	$87.00	N/A
12/12/2016	Jefferies Financial Group	Set Price Target	Buy	$88.00	N/A
12/10/2016	Cantor Fitzgerald	Reiterated Rating	Sell		N/A
12/7/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy	$120.00	N/A
12/4/2016	Bank of America	Reiterated Rating	Neutral	$68.00	N/A
12/1/2016	SVB Leerink	Boost Price Target	Outperform	$80.00 ➝ $85.00	N/A
12/1/2016	Wedbush	Reiterated Rating	Outperform	$95.00	N/A
12/1/2016	BMO Capital Markets	Set Price Target	Hold	$61.00 ➝ $83.00	N/A
12/1/2016	Jefferies Financial Group	Set Price Target	Buy	$80.00 ➝ $88.00	N/A
12/1/2016	Roth Capital	Set Price Target	Buy	$87.00	N/A
12/1/2016	Maxim Group	Boost Price Target	Buy	$57.00 ➝ $87.00	N/A
12/1/2016	Cantor Fitzgerald	Reiterated Rating	Sell	$37.00	N/A
12/1/2016	BTIG Research	Reiterated Rating	Buy	$83.00	N/A
11/30/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$95.00	N/A
11/24/2016	Janney Montgomery Scott	Reiterated Rating	Buy		N/A
11/24/2016	Jefferies Financial Group	Set Price Target	Buy	$80.00	N/A
11/23/2016	Wedbush	Reiterated Rating	Outperform	$95.00	N/A
11/10/2016	BMO Capital Markets	Initiated Coverage	Market Perform	$61.00	N/A
11/7/2016	BTIG Research	Reiterated Rating	Buy	$83.00	N/A
11/7/2016	SVB Leerink	Reiterated Rating	Outperform	$80.00	N/A
11/7/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A
11/4/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$95.00	N/A
11/4/2016	Jefferies Financial Group	Reiterated Rating	Buy	$80.00	N/A
11/3/2016	Wedbush	Reiterated Rating	Outperform	$95.00 ➝ $117.00	N/A
11/3/2016	Cantor Fitzgerald	Reiterated Rating	Sell	$37.00	N/A
10/25/2016	Piper Jaffray Companies	Set Price Target	Buy	$95.00	N/A
10/17/2016	Cowen	Reiterated Rating	Outperform		N/A
10/15/2016	Jefferies Financial Group	Set Price Target	Buy	$80.00	N/A
10/15/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$135.00	N/A
10/15/2016	BTIG Research	Reiterated Rating	Buy	$72.00 ➝ $83.00	N/A
10/14/2016	SVB Leerink	Boost Price Target	Outperform	$67.00 ➝ $80.00	N/A
10/14/2016	Wedbush	Reiterated Rating	Outperform	$117.00	N/A
10/14/2016	Cantor Fitzgerald	Downgrade	Hold ➝ Sell	$65.24 ➝ $37.00	N/A
10/14/2016	SunTrust Banks	Reiterated Rating	Buy		N/A
10/13/2016	Piper Jaffray Companies	Set Price Target	Buy	$95.00	N/A
10/3/2016	Wedbush	Reiterated Rating	Outperform	$117.00	N/A
9/30/2016	Jefferies Financial Group	Reiterated Rating	Buy	$80.00	N/A
9/29/2016	Maxim Group	Set Price Target	Buy	$85.00 ➝ $100.00	N/A
9/23/2016	Jefferies Financial Group	Reiterated Rating	Buy	$80.00	N/A
9/22/2016	Maxim Group	Set Price Target	Buy	$85.00	N/A
9/22/2016	Roth Capital	Initiated Coverage	Buy	$87.00	N/A

(Data available from 9/16/2016 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/18/2021

0 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/20/2021

0 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/19/2021

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/19/2021

0 very positive mentions
10 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/18/2021

4 very positive mentions
8 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

7/18/2021

5 very positive mentions
17 positive mentions
5 negative mentions
1 very negative mentions

Mentions as of

8/17/2021

1 very positive mentions
8 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

9/16/2021

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Today's Range

Now: $17.73

$17.27

$17.80

50 Day Range

MA: $22.01

$17.36

$30.57

52 Week Range

Now: $17.73

$17.14

$59.32

Volume

13,309 shs

Average Volume

1,657,893 shs

Market Capitalization

$1.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Frequently Asked Questions

What sell-side analysts currently cover shares of bluebird bio?

The following Wall Street sell-side analysts have issued stock ratings on bluebird bio in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Canaccord Genuity, Jefferies Financial Group Inc., JPMorgan Chase & Co., Maxim Group, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wedbush, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for BLUE.

What is the current price target for bluebird bio?

16 Wall Street analysts have set twelve-month price targets for bluebird bio in the last year. Their average twelve-month price target is $37.81, suggesting a possible upside of 115.1%. Royal Bank of Canada has the highest price target set, predicting BLUE will reach $93.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $18.00 for bluebird bio in the next year.
View the latest price targets for BLUE.

What is the current consensus analyst rating for bluebird bio?

bluebird bio currently has 17 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BLUE, but not buy more shares or sell existing shares.
View the latest ratings for BLUE.

What other companies compete with bluebird bio?

Other companies that are similar to bluebird bio include Abcam, Editas Medicine, Recursion Pharmaceuticals, Ablynx, Iovance Biotherapeutics, SpringWorks Therapeutics, Bavarian Nordic A/S, Allogene Therapeutics, Relay Therapeutics, Kymera Therapeutics, Translate Bio, BioCryst Pharmaceuticals, Cortexyme, NanoString Technologies and Instil Bio.

How do I contact bluebird bio's investor relations team?

bluebird bio's physical mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (339) 499-9300 and its investor relations email address is [email protected] The official website for bluebird bio is www.bluebirdbio.com.

NASDAQ:BLUE - bluebird bio Stock Price Target and Predictions

Analyst Price Target for BLUE

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.38 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of bluebird bio?

What is the current price target for bluebird bio?

What is the current consensus analyst rating for bluebird bio?

What other companies compete with bluebird bio?

How do I contact bluebird bio's investor relations team?